ResMed, Inc. Stock Plummets to New 52-Week Low of $190.45

ResMed, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 190.45 on May 29, 2026. This decline marks a significant downturn for the company, which has experienced a 1-year performance drop of 9.96%, contrasting sharply with the S&P 500's gain of 28.21% over the same period. The company's market capitalization stands at USD 43,243 million, reflecting its position within the mid-cap category. ResMed's price-to-earnings (P/E) ratio is currently at 29.00, indicating how the market values its earnings relative to its share price. Additionally, the company offers a dividend yield of 3.17%, which may appeal to income-focused investors. Financially, ResMed maintains a debt-to-equity ratio of -0.12, suggesting a conservative approach to leverage. The return on equity is reported at 23.77%, showcasing the company's efficiency in generating profits from shareholders' equity. The price-to-book ratio stands at 6.84, providing insight into the valuation of the company's assets relative to its market price.